{"disease":{"id":"bipolar-disorder-i","name":"bipolar disorder i"},"drugs":{"marketed":[{"drug_id":"cariprazine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vraylar","generic_name":"CARIPRAZINE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":"3267","mechanism":"Vraylar works by selectively blocking the D3 dopamine receptor, which helps regulate mood and behavior."},{"drug_id":"aripiprazole","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abilify","generic_name":"aripiprazole","company_name":"Generic (originally Otsuka/BMS)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Third-generation antipsychotic (D2 partial agonist)","quality_score":63,"revenue":"3000","mechanism":"Third-generation antipsychotic that acts as a partial agonist at D2 and 5-HT1A receptors, stabilizing dopamine activity rather than simply blocking it."},{"drug_id":"aripiprazole","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abilify","generic_name":"aripiprazole","company_name":"Generic (originally Otsuka/BMS)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Third-generation antipsychotic (D2 partial agonist)","quality_score":63,"revenue":"3000","mechanism":"Third-generation antipsychotic that acts as a partial agonist at D2 and 5-HT1A receptors, stabilizing dopamine activity rather than simply blocking it."},{"drug_id":"fluoxetine","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prozac","generic_name":"fluoxetine","company_name":"Eli Lilly and Company","drug_phase":"marketed","molecular_target":"Serotonin reuptake transporter","drug_class":"Selective Serotonin Reuptake Inhibitor (SSRI)","quality_score":81,"revenue":"1000.0","mechanism":"Fluoxetine inhibits CNS neuronal uptake of serotonin, though exact mechanism unknown."},{"drug_id":"olanzapine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyprexa","generic_name":"olanzapine","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":"300","mechanism":null},{"drug_id":"olanzapine","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyprexa","generic_name":"olanzapine","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":"300","mechanism":null},{"drug_id":"olanzapine","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyprexa","generic_name":"olanzapine","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":"300","mechanism":null},{"drug_id":"chlorpromazine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thorazine","generic_name":"chlorpromazine","company_name":"Generic (originally Rhône-Poulenc/Sanofi)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Sphingomyelin phosphodiesterase, 5-hydroxytryptamine receptor 1E","drug_class":"Typical antipsychotic (first-generation, phenothiazine)","quality_score":31,"revenue":null,"mechanism":""},{"drug_id":"lithium-citrate","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithium Citrate","generic_name":"LITHIUM CITRATE","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Glycogen synthase kinase-3","drug_class":"lithium","quality_score":10,"revenue":null,"mechanism":"Lithium Citrate works by inhibiting glycogen synthase kinase-3, a key enzyme involved in the regulation of various cellular processes."},{"drug_id":"lithium-citrate","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithium Citrate","generic_name":"LITHIUM CITRATE","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Glycogen synthase kinase-3","drug_class":"lithium","quality_score":10,"revenue":null,"mechanism":"Lithium Citrate works by inhibiting glycogen synthase kinase-3, a key enzyme involved in the regulation of various cellular processes."},{"drug_id":"quetiapine","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seroquel","generic_name":"quetiapine","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"quetiapine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seroquel","generic_name":"quetiapine","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"quetiapine","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seroquel","generic_name":"quetiapine","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"sodium valproate","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epilim","generic_name":"sodium valproate","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"asenapine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Saphris","generic_name":"ASENAPINE","company_name":"Hisamitsu","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2C","drug_class":"Atypical Antipsychotic [EPC]","quality_score":67,"revenue":null,"mechanism":"Saphris works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2C."},{"drug_id":"phenytoin","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenytoin Sodium","generic_name":"PHENYTOIN","company_name":"Viatris","drug_phase":"marketed","molecular_target":"Sodium channel protein type 2 subunit alpha","drug_class":"Anti-epileptic Agent","quality_score":70,"revenue":null,"mechanism":"Phenytoin Sodium works by stabilizing the threshold against hyperexcitability caused by excessive stimulation."},{"drug_id":"carbamazepine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tegretol","generic_name":"carbamazepine","company_name":"Novartis AG (originally Geigy)","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"Mood Stabilizer [EPC]","quality_score":62,"revenue":null,"mechanism":"Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain."},{"drug_id":"carbamazepine","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tegretol","generic_name":"carbamazepine","company_name":"Novartis AG (originally Geigy)","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"Mood Stabilizer [EPC]","quality_score":62,"revenue":null,"mechanism":"Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain."},{"drug_id":"lamotrigine","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lamictal","generic_name":"lamotrigine","company_name":"GSK","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 1 subunit alpha","drug_class":"Anti-epileptic Agent [EPC]","quality_score":55,"revenue":null,"mechanism":null},{"drug_id":"risperidone","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Risperdal","generic_name":"risperidone","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors for schizophrenia and bipolar disorder."},{"drug_id":"risperidone","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Risperdal","generic_name":"risperidone","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors for schizophrenia and bipolar disorder."},{"drug_id":"ziprasidone","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Geodon","generic_name":"ziprasidone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aspartate aminotransferase, cytoplasmic, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical antipsychotic (second-generation)","quality_score":10,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors with the least metabolic side effects in its class."},{"drug_id":"ziprasidone","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Geodon","generic_name":"ziprasidone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aspartate aminotransferase, cytoplasmic, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical antipsychotic (second-generation)","quality_score":10,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors with the least metabolic side effects in its class."},{"drug_id":"carbamazepin","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carbamazepin","company_name":"Enanta Pharmaceuticals, Inc","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"carbamazepin","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carbamazepin","company_name":"Enanta Pharmaceuticals, Inc","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"valproic-acid","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depakene","generic_name":"valproic acid","company_name":"Generic (originally Abbott/AbbVie)","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"Anti-epileptic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":"Broad-spectrum anticonvulsant that enhances GABA activity, blocks sodium and calcium channels, and inhibits histone deacetylase."},{"drug_id":"prozac","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prozac","company_name":"RenJi Hospital","drug_phase":"marketed","molecular_target":"Equilibrative nucleoside transporter 4, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"lithium","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithobid","generic_name":"lithium carbonate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3","drug_class":"Mood stabilizer","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"lithium","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithobid","generic_name":"lithium carbonate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3","drug_class":"Mood stabilizer","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"phenobarbitone","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phenobarbitone","company_name":"Institute of Child Health","drug_phase":"phase_1","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lithium-carbonate","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithium Carbonate","generic_name":"LITHIUM CARBONATE","company_name":"","drug_phase":"marketed","molecular_target":"Glycogen synthase kinase-3","drug_class":"lithium carbonate","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"lithium-carbonate","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithium Carbonate","generic_name":"LITHIUM CARBONATE","company_name":"","drug_phase":"marketed","molecular_target":"Glycogen synthase kinase-3","drug_class":"lithium carbonate","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"lurasidone","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Latuda","generic_name":"LURASIDONE","company_name":"Sunovion Pharms Inc","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Atypical Antipsychotic","quality_score":80,"revenue":null,"mechanism":"Latuda works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2A, which helps to regulate mood and reduce symptoms of psychosis."},{"drug_id":"primidone","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mysoline","generic_name":"PRIMIDONE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 3","drug_class":"Anti-epileptic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"doxepin","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zonalon","generic_name":"DOXEPIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Tricyclic Antidepressant","quality_score":80,"revenue":null,"mechanism":"Zonalon works by blocking histamine H1 receptors in the brain, which helps to reduce anxiety and itching, and improve mood."},{"drug_id":"dilantin","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilantin","generic_name":"Phenytoin Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3","drug_class":"phenytoin","quality_score":80,"revenue":null,"mechanism":"Phenytoin exerts its therapeutic effect by voltage-dependent blockade of membrane sodium channels."},{"drug_id":"seroquel","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Seroquel","company_name":"University of Pittsburgh","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"seroquel","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Seroquel","company_name":"University of Pittsburgh","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"seroquel","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Seroquel","company_name":"University of Pittsburgh","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"quetiapin","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapin","company_name":"Sykehuset Innlandet HF","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"quetiapin","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapin","company_name":"Sykehuset Innlandet HF","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"quetiapin","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapin","company_name":"Sykehuset Innlandet HF","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"risperdal","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Risperdal","company_name":"Ohio State University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"risperdal","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Risperdal","company_name":"Ohio State University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zyprexa","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zyprexa","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zyprexa","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zyprexa","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zyprexa","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zyprexa","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"samidorphan","indication_name":"Bipolar I Disorder - Acute Manic or Mixed Episodes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lybalvi","generic_name":"SAMIDORPHAN","company_name":"Alkermes Inc","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":"Lybalvi blocks the action of opioids at their receptor sites in the brain."},{"drug_id":"divalproex","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Divalproex","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"samidorphan","indication_name":"Bipolar I Disorder - Maintenance Monotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lybalvi","generic_name":"SAMIDORPHAN","company_name":"Alkermes Inc","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":"Lybalvi blocks the action of opioids at their receptor sites in the brain."},{"drug_id":"lamotrigine","indication_name":"Bipolar Disorder - Maintenance Treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lamictal","generic_name":"lamotrigine","company_name":"GSK","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 1 subunit alpha","drug_class":"Anti-epileptic Agent [EPC]","quality_score":55,"revenue":null,"mechanism":null},{"drug_id":"samidorphan-l-malate","indication_name":"Bipolar I Disorder - Acute Manic or Mixed Episodes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SAMIDORPHAN L-MALATE","company_name":"","drug_phase":"marketed","molecular_target":"dopamine and serotonin type 2 (5HT2) receptors, opioid receptors","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":"Olanzapine's efficacy may be due to dopamine and serotonin type 2 antagonism, while samidorphan acts through opioid receptor antagonism."},{"drug_id":"samidorphan-l-malate","indication_name":"Bipolar I Disorder - Maintenance Monotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SAMIDORPHAN L-MALATE","company_name":"","drug_phase":"marketed","molecular_target":"dopamine and serotonin type 2 (5HT2) receptors, opioid receptors","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":"Olanzapine's efficacy may be due to dopamine and serotonin type 2 antagonism, while samidorphan acts through opioid receptor antagonism."},{"drug_id":"abilify","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abilify","company_name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"abilify","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abilify","company_name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":19,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":55,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT06115200","title":"Norwegian Adult Mental Health Registry","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Helse Stavanger HF","has_results":false},{"nct_id":"NCT06641726","title":"Creating a Global Research Database That Connects Genetic Information and Long-term Health Data to Improve Personalized Treatment for People With Serious Mental Illness","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Akrivia Health","has_results":false},{"nct_id":"NCT07281729","title":"Investigation on Risk Factors for Suicide Among Chinese Patients With Mood Disorders","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":25000,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT06818227","title":"MonPsy&Moi: A Digital Platform for Collecting Patient-Reported Experience and Outcome Measures in Psychiatry","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":23660,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT05206734","title":"Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health","phase":"","overall_status":"COMPLETED","enrollment_count":19469,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT00024635","title":"Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers","phase":"","overall_status":"RECRUITING","enrollment_count":16000,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT02451670","title":"Reducing Cardiovascular Risk in Adults With Serious Mental Illness","phase":"NA","overall_status":"COMPLETED","enrollment_count":10347,"lead_sponsor_name":"HealthPartners Institute","has_results":true},{"nct_id":"NCT05480150","title":"Chinese Longitudinal and Systematic Study of Bioplar Disorder","phase":"NA","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT07129408","title":"Epidemiological Study on the Prevalence of Mental Disorders in Slovakia","phase":"","overall_status":"COMPLETED","enrollment_count":3100,"lead_sponsor_name":"Comenius University","has_results":false},{"nct_id":"NCT06433635","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2726,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT00001260","title":"Brain Tissue Collection for Neuropathological Studies","phase":"","overall_status":"TERMINATED","enrollment_count":2161,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT07212075","title":"Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups","phase":"","overall_status":"RECRUITING","enrollment_count":1809,"lead_sponsor_name":"Forschungsinstitut der Diabetes Akademie Mergentheim","has_results":false},{"nct_id":"NCT07314190","title":"Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1799,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false},{"nct_id":"NCT03656770","title":"Measuring Beliefs and Norms About Persons With Mental Illness","phase":"NA","overall_status":"COMPLETED","enrollment_count":1782,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT03740139","title":"The Police-Mental Health Linkage System","phase":"NA","overall_status":"COMPLETED","enrollment_count":1405,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT03451630","title":"Integrated Care (IC) Models for Patient-Centered Outcomes","phase":"NA","overall_status":"COMPLETED","enrollment_count":1400,"lead_sponsor_name":"University of Pittsburgh","has_results":true},{"nct_id":"NCT07239843","title":"Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychiatric Symptoms in Neurodegenerative Diseases and Mental Disorders","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1310,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false},{"nct_id":"NCT00006177","title":"Child & Adolescent Bipolar Disorder Brain Imaging and Treatment Study","phase":"","overall_status":"COMPLETED","enrollment_count":1303,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT05669703","title":"NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder","phase":"","overall_status":"RECRUITING","enrollment_count":1260,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT02845440","title":"Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness","phase":"NA","overall_status":"COMPLETED","enrollment_count":1165,"lead_sponsor_name":"Massachusetts General Hospital","has_results":true},{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT06657430","title":"A Study on the Preference of Risperidone Dosage Forms","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT03573297","title":"A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":901,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04209296","title":"Chart Review of Patients Undergoing Ketamine Infusions","phase":"","overall_status":"COMPLETED","enrollment_count":891,"lead_sponsor_name":"Brain and Cognition Discovery Foundation","has_results":false},{"nct_id":"NCT05801562","title":"Development of a Software Tool, Using Artificial Intelligence, That Integrates Clinical, Biological, Genetic and Imaging Data to Predict Diagnosis and Outcome of Depressed Patients in Order to Enhance Prognosis and Limiting Healthcare Costs.","phase":"","overall_status":"UNKNOWN","enrollment_count":730,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT06053346","title":"Partners in Wellness: Evaluation of a Pay for Performance Program for High-Utilizers of Mental Health Services","phase":"NA","overall_status":"COMPLETED","enrollment_count":652,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT07031817","title":"Validation of a Composite Medical Device Using a Blood Biomarker-based Algorithm and MDQ for the Diagnosis of Bipolar Disorder","phase":"NA","overall_status":"RECRUITING","enrollment_count":623,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT05127837","title":"CBTpro: Scaling up CBT for Psychosis Using Simulated Patients and Spoken Language Technologies","phase":"NA","overall_status":"COMPLETED","enrollment_count":601,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT05529576","title":"Multi-factor Model Constraction for Early Warning and Diagnosis of MDD","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT06424613","title":"Effects of Lithium on Suicide Prevention in Adolescents and Young Adults With Bipolar Disorder in China","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT07033923","title":"Neuro-computational Study of Thymic Fluctuations in Mood Disorders","phase":"NA","overall_status":"RECRUITING","enrollment_count":588,"lead_sponsor_name":"Centre Hospitalier St Anne","has_results":false},{"nct_id":"NCT06978452","title":"Behavioural Development, Long-term Outcomes and Opportunities to Optimize Youth Mental Health Trajectories","phase":"","overall_status":"RECRUITING","enrollment_count":560,"lead_sponsor_name":"Douglas Mental Health University Institute","has_results":false},{"nct_id":"NCT07151846","title":"Digital Phenotypes for Predicting Depression","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":540,"lead_sponsor_name":"Korea University Anam Hospital","has_results":false},{"nct_id":"NCT04812379","title":"Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)","phase":"","overall_status":"COMPLETED","enrollment_count":535,"lead_sponsor_name":"Otsuka Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT01928446","title":"Lithium for Suicidal Behavior in Mood Disorders","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":519,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT02670538","title":"Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":493,"lead_sponsor_name":"Forest Laboratories","has_results":true},{"nct_id":"NCT02670551","title":"Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":488,"lead_sponsor_name":"Forest Laboratories","has_results":true},{"nct_id":"NCT00538629","title":"Non Interventional Study In Bipolar Disorder And Schizophrenia With Zeldox","phase":"","overall_status":"COMPLETED","enrollment_count":471,"lead_sponsor_name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","has_results":true},{"nct_id":"NCT05658510","title":"Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":452,"lead_sponsor_name":"BioXcel Therapeutics Inc","has_results":false},{"nct_id":"NCT06929273","title":"A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05603819","title":"Clinical Validation Study for EDIT-B Test: an Aid for Differential Diagnosis of Bipolar Disorder, Based on RNA Editing Blood Biomarkers","phase":"","overall_status":"COMPLETED","enrollment_count":418,"lead_sponsor_name":"Alcediag","has_results":false},{"nct_id":"NCT01244815","title":"Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":404,"lead_sponsor_name":"Organon and Co","has_results":true},{"nct_id":"NCT07444463","title":"Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Clinical Applications","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Central South University","has_results":false},{"nct_id":"NCT04972708","title":"Genetics of COVID-19 Risks & Resilience in Bipolar Disorder","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Medical University of Graz","has_results":false},{"nct_id":"NCT04664374","title":"Characterizing MyMood Patterns of Use","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Sunnybrook Health Sciences Centre","has_results":false},{"nct_id":"NCT03481049","title":"Individualizing Incentives for Alcohol in the Severely Mentally Ill","phase":"NA","overall_status":"COMPLETED","enrollment_count":392,"lead_sponsor_name":"Washington State University","has_results":true},{"nct_id":"NCT05965232","title":"FIbrosis and Steatosis in Patients With Psychiatric Illness","phase":"","overall_status":"COMPLETED","enrollment_count":385,"lead_sponsor_name":"Centre Hospitalier Esquirol","has_results":false},{"nct_id":"NCT03287869","title":"A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":381,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT04276883","title":"Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":380,"lead_sponsor_name":"BioXcel Therapeutics Inc","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}